211 related articles for article (PubMed ID: 27806324)
1. PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK.
Lu T; Zou Y; Xu G; Potter JA; Taylor GL; Duan Q; Yang Q; Xiong H; Qiu H; Ye D; Zhang P; Yu S; Yuan X; Zhu F; Wang Y; Xiong H
Oncotarget; 2016 Dec; 7(50):83017-83030. PubMed ID: 27806324
[TBL] [Abstract][Full Text] [Related]
2. PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms.
Li XL; Zhou J; Chan ZL; Chooi JY; Chen ZR; Chng WJ
Oncotarget; 2015 Nov; 6(34):36689-99. PubMed ID: 26452133
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
[TBL] [Abstract][Full Text] [Related]
4. PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells.
Yoshikawa N; Kajiyama H; Nakamura K; Utsumi F; Niimi K; Mitsui H; Sekiya R; Suzuki S; Shibata K; Callen D; Kikkawa F
Oncol Rep; 2016 May; 35(5):2543-52. PubMed ID: 26986846
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.
Patyka M; Sharifi Z; Petrecca K; Mansure J; Jean-Claude B; Sabri S
Oncotarget; 2016 Sep; 7(37):60245-60269. PubMed ID: 27533246
[TBL] [Abstract][Full Text] [Related]
6. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.
Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS
Clin Cancer Res; 2011 May; 17(9):2830-41. PubMed ID: 21415220
[TBL] [Abstract][Full Text] [Related]
7. PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53.
Sobhani M; Abdi J; Manujendra SN; Chen C; Chang H
Cancer Biol Ther; 2015; 16(5):799-806. PubMed ID: 25803193
[TBL] [Abstract][Full Text] [Related]
8. MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.
Saha MN; Abdi J; Yang Y; Chang H
Oncotarget; 2016 Feb; 7(6):7149-60. PubMed ID: 26771839
[TBL] [Abstract][Full Text] [Related]
9. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
Zache N; Lambert JM; Wiman KG; Bykov VJ
Cell Oncol; 2008; 30(5):411-8. PubMed ID: 18791272
[TBL] [Abstract][Full Text] [Related]
10. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance.
Tessoulin B; Descamps G; Moreau P; Maïga S; Lodé L; Godon C; Marionneau-Lambot S; Oullier T; Le Gouill S; Amiot M; Pellat-Deceunynck C
Blood; 2014 Sep; 124(10):1626-36. PubMed ID: 25006124
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
Haagensen EJ; Thomas HD; Mudd C; Tsonou E; Wiggins CM; Maxwell RJ; Moore JD; Newell DR
Eur J Cancer; 2016 Mar; 56():69-76. PubMed ID: 26820797
[TBL] [Abstract][Full Text] [Related]
12. PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein.
Stuber G; Flaberg E; Petranyi G; Otvös R; Rökaeus N; Kashuba E; Wiman KG; Klein G; Szekely L
Mol Cancer; 2009 Mar; 8():23. PubMed ID: 19323829
[TBL] [Abstract][Full Text] [Related]
13. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
14.
Meher RK; Mir SA; Anisetti SS
J Biomol Struct Dyn; 2024 May; 42(8):4169-4184. PubMed ID: 37272907
[TBL] [Abstract][Full Text] [Related]
15. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
Saha MN; Jiang H; Yang Y; Reece D; Chang H
Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633
[TBL] [Abstract][Full Text] [Related]
16. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.
Li Y; Mao Y; Brandt-Rauf PW; Williams AC; Fine RL
Mol Cancer Ther; 2005 Jun; 4(6):901-9. PubMed ID: 15956247
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
[TBL] [Abstract][Full Text] [Related]
18. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
20. The small molecule AU14022 promotes colorectal cancer cell death via p53-mediated G2/M-phase arrest and mitochondria-mediated apoptosis.
Ryu H; Nam KY; Kim JS; Hwang SG; Song JY; Ahn J
J Cell Physiol; 2018 Jun; 233(6):4666-4676. PubMed ID: 29030986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
